(AOF) – Ose Immunotherapeutics reduced its losses in the first half of 2022. The net loss amounted to 1.979 million euros against a loss of 11.488 million in the first half of 2021. The operating loss amounted to 3.425 million against a loss of 11 .58 million a year earlier. Turnover jumped 78% to 16 million, supported by milestone payments from its partners.
The biotech has received a €10 million milestone payment under the licensing and collaboration agreement with Boehringer Ingelheim on BI 765063, a SIRPα inhibitor on the SIRPα/CD47 myeloid axis.
It also received a €5 million milestone payment under the licensing agreement with Veloxis Pharmaceuticals Inc. for FR104, an anti-CD28, in transplantation.
As of June 30, 2022, available cash amounted to €31 million, ensuring financial visibility until the third quarter of 2023.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.